Weekly Digest – May 2026 Weekly Digest – May 2026 14 May 2026: Astellas Pharma sNDA in Japan for PADCEV in combination with Keytruda for cisplatin-eligible patients with muscle-invasive Bladder cancer Astellas has submitted an sNDA in Japan seeking approval […]
Weekly Digest – May 2026 Weekly Digest – May 2026 08 May 2026: The sNDA for Sacituzumab Tirumotecan in combination with Pembrolizumab as 1L treatment for PD-L1 positive NSCLC accepted for review by NMPA Kelun-Biotech has reached another major regulatory […]
Weekly Digest – May 2026 Weekly Digest – May 2026 11 May 2026: HS-20093 granted Breakthrough Therapy Designation by NMPA for Esophageal cancer treatment Hansoh Pharma has secured another important regulatory milestone after China’s NMPA granted Breakthrough Therapy Designation to […]
Weekly Digest – May 2026 Weekly Digest – May 2026 11 May 2026: SYS6010 has received another BTD in China for the treatment of patients with locally advanced or metastatic ESCC CSPC Pharmaceutical has secured another Breakthrough Therapy Designation from […]
Weekly Digest – May 2026 Weekly Digest – May 2026 12 May 2026: Emiltatug Ledadotin has been granted Breakthrough Therapy Designation by the U.S. FDA for the treatment of Adenoid cystic carcinoma Servier has secured U.S. FDA Breakthrough Therapy Designation […]
Weekly Digest – May 2026 Weekly Digest – May 2026 11 May 2026: Zai Lab announced that Zocilurtatug Pelitecan has received U.S. FDA FTD for the treatment of extrapulmonary Neuroendocrine carcinomas Zai Lab has received U.S. FDA Fast Track Designation […]
Weekly Digest – May 2026 Weekly Digest – May 2026 07 May 2026: Daiichi Sankyo Korea and AstraZeneca Korea received approval for two additional Enhertu indications: 1L HER2-positive metastatic Breast cancer and 2L HER2-positive metastatic Gastric cancer Enhertu has secured […]
Weekly Digest – May 2026 Weekly Digest – May 2026 06 May 2026: HLX43 received PMDA acknowledgment to initiate a global Phase 2/3 trial in squamous Non-Small Cell Lung Cancer Henlius has achieved a key milestone for its anti-PD-L1 ADC […]
Weekly Digest – May 2026 Weekly Digest – May 2026 07 May 2026: InnoCare Pharma’s independently developed CDH17-targeted ADC innovative drug ICP B208 has been approved for clinical trials InnoCare Pharma has expanded its ADC pipeline after receiving National Medical […]
Weekly Digest – May 2026 Weekly Digest – May 2026 07 May 2026: ArriVent announces IND clearance for novel tetravalent MUC16/NaPi2b targeting ADC ARR-002 with initial focus in Ovarian and Endometrial cancers ArriVent BioPharma has received IND clearance for ARR-002, […]
